Lindsay Kehoe

Bio:

Lindsay Kehoe, Senior Project Manager and Lead Emerging Programs at the Clinical Trials Transformation Initiative (CTTI), manages the development and implementation of projects in digital health trials, data quality, disease progression modeling, artificial intelligence, and integrating clinical research into clinical practice. Ms. Kehoe serves on an advisory board for the Innovative Medicines Initiative’s Trials@Home consortium and is engaged in the Real-World Evidence Collaborative at Duke Margolis Institute for Health Policy. She is also a member of Duke Margolis’ ACT@POC coalition, a multi-partner group that aims to drive the implementation of large-scale clinical trials at the community level. 

Ms. Kehoe is a rare disease specialist and pediatric genetic counselor. She has prior experience educating health care providers, patients, and patient advocacy groups about genetic and rare diseases under the National Institute of Health’s National Center for Advancing Translational Sciences (NCATS) Genetic and Rare Disease (GARD) program. Ms. Kehoe coordinated the lysosomal storage disorders program and numerous clinical trials within the Genetics Division at Children’s National Medical Center. She also served on the hospital’s Institutional Review Board. Ms. Kehoe has worked in early phase drug development at Millennium Pharmaceuticals (now Takeda Pharmaceuticals) and in post-marketing laboratory surveillance at Sanofi Genzyme. She is an alumna of the University of Virginia and of Boston University School of Medicine’s graduate school.